Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Reported Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2025
-18.1%
Period ended Dec 31, 2025
Change on a year earlier
+0.7 pts
-18.8% in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Reported Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -18.1% | +0.7 pts | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | -18.8% | +44.5 pts | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | -63.3% | -82.3 pts | SEC Filing (0001628280-24-002009) ↗ |
| FY2022 | Dec 31, 2022 | 19.0% | -76.4 pts | SEC Filing (0001628280-23-001516) ↗ |
| FY2021 | Dec 31, 2021 | 95.4% | -17.6 pts | SEC Filing (0001104659-22-007648) ↗ |
| FY2020 | Dec 31, 2020 | 113.0% | +113.8 pts | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | -0.8% | – | SEC Filing (0001104659-20-005717) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Reported Sales Growth (%) (%), annual FY2019–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rapid-leg-yoy-rep
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.